Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

    Hjortsø, M. D., Larsen, S. K., Kongsted, P., Met, Özcan, Frøsig, T. M., Andersen, G. H., Ahmad, S. M., Svane, Inge Marie, Becker, J. C., Straten, P. T. & Andersen, Mads Hald, Jan 2015, In: OncoImmunology. 4, 1, e968480.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial

    Holmberg-Thydén, S., Dufva, I. H., Gang, Anne Ortved, Breinholt, M. F., Schejbel, L., Andersen, M. K., Kadivar, M., Svane, Inge Marie, Grønbæk, Kirsten, Hadrup, S. R. & El Fassi, D., 2022, In: Cancer Immunology, Immunotherapy. 71, p. 433-444

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Holmen Olofsson, G., Pedersen, S. R., Aehnlich, P., Svane, Inge Marie, Idorn, M. & thor Straten, P., 2021, In: Cytotherapy. 23, 7, p. 582-589

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

    Holmstroem, R. B., Dahl, E. K., Helms, Morten, Nielsen, H. V., Andersen, J. B., Bjerrum, Jakob Tveiten , Svane, Inge Marie, Ellebaek, E. & Seidelin, Jakob Benedict, 2022, In: BMJ Open Gastroenterology. 9, 1, 4 p., e000989.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

    Holmstroem, R. B., Nielsen, Ole Haagen, Jacobsen, Søren, Riis, Lene Buhl, Theile, S., Bjerrum, Jakob Tveiten , Vilmann, Peter, Johansen, Julia Sidenius, Boisen, M. K., Eefsen, R. H. L., Svane, Inge Marie, Nielsen, Dorte Lisbet & Chen, I. M., 2022, In: Journal for ImmunoTherapy of Cancer. 10, 9

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

    Holmstrom, M. O., Martinenaite, E., Ahmad, S. M., Met, Özcan, Friese, C., Kjaer, L., Riley, C. H., Straten, P. T., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 1 Feb 2018, In: Leukemia. 32, 2, p. 429-437

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

    Holmström, M. O., Ahmad, S. M., Klausen, U., Bendtsen, S. K., Martinenaite, E., Riley, C. H., Svane, Inge Marie, Kjær, L., Skov, V., Ellervik, Christina, Pallisgaard, N., Hasselbalch, H. C. & Andersen, Mads Hald, 2019, In: Blood Cancer Journal. 9, 2, 8.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

    Holmström, M. O., Riley, C. H., Svane, Inge Marie, Hasselbalch, H. C. & Andersen, Mads Hald, Dec 2016, In: Leukemia. 30, 12, p. 2413-2416 14 p.

    Research output: Contribution to journalLetterResearchpeer-review

  9. Published

    The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

    Holmström, M. O., Hjortso, M. D., Ahmad, S. M., Met, Özcan, Martinenaite, E., Riley, C., Straten, P., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2017, In: Leukemia. 31, p. 495-498

    Research output: Contribution to journalLetterResearchpeer-review

  10. Published

    Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

    Holmström, M. O., Riley, C. H., Skov, V., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2018, In: OncoImmunology. 7, 6, e1433521.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1...9 10 11 12 13 14 15 16 ...28 Next

ID: 4054758